Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years
British Journal of Dermatology · 2024
DOI: 10.1093/bjd/ljae131 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Hiroo Yokozeki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Hauptthemen laut MEDLINE: Prurigo, Quality of Life, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Maruho Co. Ltd, Chugai Pharmaceutical Co. Ltd.
Abstract (Originalsprache)
Background
Prurigo nodularis (PN), a chronic inflammatory skin condition, adversely affects the quality of life of affected individuals. Current treatment options for PN in Japan are limited.
Objectives
To evaluate the optimal dose, efficacy and safety of long-term treatment with nemolizumab in patients with PN in Japan.
Methods
In a 16-week double-blind phase II/III study, patients aged ≥ 13 years with PN were randomly assigned (1 : 1 : 1) to nemolizumab 30-mg, 60-mg or placebo groups, with concomitant topical corticosteroids, every 4 weeks. The primary efficacy endpoint was the percentage change in the weekly mean Peak Pruritus Numerical Rating Scale (PP-NRS) score (range 0–10, with higher scores indicating worse itching) from baseline to week 16. Secondary efficacy endpoints assessed the impact of treatment on pruritus, PN severity, sleep and quality of life.
Results
At week 16, the least-squares mean percentage change from baseline in the PP-NRS score was −61.1% in the nemolizumab 30-mg group (n = 77), −56.0% in the 60-mg group (n = 76), and −18.6% in the placebo group (n = 76). Differences between both nemolizumab groups and placebo were significant; the difference between the 30-mg and placebo groups was −42.5% [95% confidence interval (CI) −51.9 to −33.1; P < 0.0001], and between the 60-mg and placebo groups was −37.4% (95% CI −46.7 to −28.1; P < 0.0001). Patients treated with nemolizumab also had greater improvements in the number and severity of prurigo nodules, and in sleep and quality of life compared with the placebo group. Both nemolizumab doses were well tolerated.
Conclusions
Improvements in PN were greater following nemolizumab treatment, despite continuation of topical corticosteroids in both groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
- Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Clinical Development Department, Maruho Co. Ltd, Kyoto, Japan.
ORCID-Profile: Hiroo Yokozeki, Hiroyuki Murota, Hiroshi Komazaki
Förderung
- Maruho Co. Ltd
- Chugai Pharmaceutical Co. Ltd
Zitieren
APA
Yokozeki, H., Murota, H., Matsumura, T., Komazaki, H., & Nemolizumab-JP11 Study Group (2024). Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae131
Vancouver
Yokozeki H, Murota H, Matsumura T, Komazaki H, Nemolizumab-JP11 Study Group. Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae131
BibTeX
@article{Yokozeki2024,
author = {Yokozeki, Hiroo and Murota, Hiroyuki and Matsumura, Takayo and Komazaki, Hiroshi and Nemolizumab-JP11 Study Group, Nemolizumab-JP11 Study Group},
title = {Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II/III clinical study in patients aged ≥ 13 years},
journal = {British Journal of Dermatology},
year = {2024},
doi = {10.1093/bjd/ljae131}
}
EUVIMED